Evidence map›Paper›PMID 26658650›Full record

ReviewCurrent opinion in infectious diseases2016

The immunopathogenesis of cryptococcal immune reconstitution inflammatory syndrome: understanding a conundrum.

David B Meya, Yukari C Manabe, David R Boulware, Edward N Janoff

Abstract readReview
In one paragraph

Review in Current opinion in infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Foxp3Research square · 2025
    Article
  5. Observational
  6. Article
  7. Article
  8. Molecular Diagnostics ofDiseases (Basel, Switzerland) · 2024
    Review
  9. Global trends inFrontiers in immunology · 2024
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

David B MeyaaInfectious Disease Institute, Makerere University, Kampala, Uganda bDepartment of Medicine, Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota, Minneapolis, Minnesota, USA cSchool of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda dDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, Maryland eMucosal and Vaccine Research Program Colorado (MAVRC), University of Colorado Denver fDenver Veterans Affairs Medical Center, Denver, Colorado, USA.
Yukari C Manabe
David R Boulware
Edward N Janoff
Johns Hopkins University · USMakerere University · UGUniversity of Colorado Denver · USUniversity of Minnesota · US

Funding

Trial for the Optimal Timing of HIV Therapy after Cryptococcal MeningitisU01AI089244 · NIAID · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R · 2010 to 2014
$7.6M
Infectious Disease Training in Clinical InvestigationT32AI055433 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI David R Boulware · 2003 to 2026
$6.1M
HIV Co-infections in Uganda: TB, Cryptococcus, and Viral Hepatitis.D43TW009771 · FIC · JOHNS HOPKINS UNIVERSITY · PI CASTELNUOVO, BARBARA, KAMBUGU, ANDREW DDUNGU · 2014 to 2023
$3.3M
Mechanisms of Impaired HIV-associated B cell and Pneumococcal Vaccine responsesR01AI108479 · NIAID · UNIVERSITY OF COLORADO DENVER · PI JANOFF, EDWARD N · 2014 to 2018
$2.3M
Outcomes of Cryptococcal Meningitis in UgandaK24AI096925 · NIAID · UNIVERSITY OF MINNESOTA · PI BOHJANEN, PAUL R · 2011 to 2015
$1.0M
The immunopathogenesis of HIV-related Immune Reconstitution Inflammatory SyndromeR01AI078934 · NIAID · INFECTIOUS DISEASES INSTITUTE · PI KAMBUGU, ANDREW DDUNGU, MEYA, DAVID BISAGAYA · 2010 to 2013
$415k
Impact of HIV and HIV therapy on the Etiology and Outcome of Meningitis in UgandaR21NS065713 · NINDS · UNIVERSITY OF MINNESOTA · PI BOHJANEN, PAUL R, BOULWARE, DAVID R · 2010 to 2011
$276k
FIC NIH HHS D43 TW009771NIAID NIH HHS AI108479NIAID NIH HHS K24 AI096925NIAID NIH HHS K24AI096925NIAID NIH HHS R01 AI078934NIAID NIH HHS R01AI078934NIAID NIH HHS R01 AI108479NIAID NIH HHS R01AI108479NIAID NIH HHS T32 AI055433NIAID NIH HHS T32AI055433NIAID NIH HHS U01 AI089244NIAID NIH HHS U01AI089244NINDS NIH HHS R21 NS065713NINDS NIH HHS R21NS065713Wellcome Trust 087540
6 · The paper itself

Abstract

purpose of reviewCryptococcal meningitis causes significant mortality among HIV-infected patients, despite antifungal therapy and use of antiretroviral therapy (ART). In patients with cryptococcal meningitis, ART is often complicated by immune reconstitution inflammatory syndrome (IRIS), manifesting as unmasking of previously unrecognized subclinical infection (unmasking CM-IRIS) or paradoxical worsening of symptoms in the central nervous system after prior improvement with antifungal therapy (paradoxical CM-IRIS). We review our current understanding of the pathogenesis of this phenomenon, focusing on unifying innate and adaptive immune mechanisms leading to the development of this often fatal syndrome. RECENT

findingsWe propose that HIV-associated CD4 T-cell depletion, chemokine-driven trafficking of monocytes into cerebrospinal fluid in response to cryptococcal meningitis, and poor localized innate cytokine responses lead to inadequate cryptococcal killing and clearance of the fungus. Subsequent ART-associated recovery of T-cell signaling and restored cytokine responses, characterized by IFN-γ production, triggers an inflammatory response. The inflammatory response triggered by ART is dysregulated because of impaired homeostatic and regulatory mechanisms, culminating in the development of CM-IRIS. SUMMARY: Despite our incomplete understanding of the immunopathogenesis of CM-IRIS, emerging data exploring innate and adaptive immune responses could be exploited to predict, prevent and manage CM-IRIS and associated morbid consequences.

Indexed as

Adaptive ImmunityAIDS-Related Opportunistic InfectionsAntifungal AgentsAnti-HIV AgentsCD4-Positive T-LymphocytesHumansImmune Reconstitution Inflammatory SyndromeImmunity, InnateMeningitis, CryptococcalRisk FactorsAntifungal AgentsAnti-HIV Agents

Identifiers

PMID26658650
PMCPMC4689618
OpenAlexW2414962288

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.